Prostate cancer is the most commonly diagnosed cancer in men, accounting for nearly one fourth of all male cancer diagnoses worldwide. In 2018, over 1.2 million new cases of prostate cancer were reported globally.

While treatment options have improved significantly over the years, early detection and proper management are still key to improving the long-term survival rates of patients. Janssen Cilag, a leading pharmaceutical company, is at the forefront of research and development of innovative therapies for prostate cancer.

In this informative update, we will explore the latest developments in prostate cancer diagnosis, treatment and management.

Prostate Cancer Diagnosis

The current standard of care for diagnosis of prostate cancer is a prostate-specific antigen (PSA) blood test combined with a digital rectal examination (DRE).

However, these tests have limitations and are not always accurate in detecting prostate cancer. Janssen Cilag is involved in ongoing research and development of novel biomarkers for prostate cancer detection. One such biomarker is the Prostate Cancer Antigen 3 (PCA3) test, which measures the level of PCA3 mRNA in urine.

The PCA3 test has been shown to improve the accuracy of prostate cancer diagnosis, especially in men with elevated PSA levels. Janssen Cilag is also exploring other biomarkers such as circulating tumor cells (CTCs) and exosomes for prostate cancer detection.

Prostate Cancer Treatment

Treatment options for prostate cancer depend on various factors such as the stage and aggressiveness of the cancer, the age and overall health of the patient, and the patient’s personal preference.

Janssen Cilag offers a range of therapies for prostate cancer, including hormonal therapies, chemotherapy, and immunotherapies. Hormonal therapies work by blocking the production or action of male hormones, which stimulate the growth of prostate cancer cells. Janssen Cilag has developed several hormonal therapies such as abiraterone acetate and apalutamide.

Chemotherapy involves the use of drugs to kill cancer cells and can be used in combination with hormonal therapies. Janssen Cilag has developed docetaxel and cabazitaxel chemotherapies for prostate cancer. Immunotherapy is a relatively new approach to cancer treatment that involves stimulating the patient’s immune system to attack cancer cells.

Janssen Cilag is researching various immunotherapies for prostate cancer.

Prostate Cancer Management

Prostate cancer management involves monitoring and treating the disease while minimizing the impact on the patient’s quality of life.

Active surveillance, also known as watchful waiting, is a management strategy that involves closely monitoring the cancer but delaying treatment until necessary. This approach is often recommended for older or low-risk patients. Janssen Cilag has developed tools such as the Prostate Cancer Registry to help healthcare professionals monitor patient outcomes and inform treatment decisions.

Other management strategies include lifestyle changes such as diet and exercise, as well as supportive therapies such as pain management and psychological support for patients and their families.

Conclusion

Prostate cancer is a significant health issue for men globally. Early detection, proper diagnosis and appropriate treatment are essential to improve survival rates and maintain quality of life.

Janssen Cilag is committed to developing innovative therapies for prostate cancer and improving patient outcomes. By continuing to invest in research and development, Janssen Cilag is helping to shape the future of prostate cancer management.